1.Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
Yoon Jin CHOI ; Yong Chan LEE ; Jung Mogg KIM ; Jin Il KIM ; Jeong Seop MOON ; Yun Jeong LIM ; Gwang Ho BAIK ; Byoung Kwan SON ; Hang Lak LEE ; Kyoung Oh KIM ; Nayoung KIM ; Kwang Hyun KO ; Hye-Kyung JUNG ; Ki-Nam SHIM ; Hoon Jai CHUN ; Byung-Wook KIM ; Hyuk LEE ; Jie-Hyun KIM ; Hyunsoo CHUNG ; Sang Gyun KIM ; Jae Young JANG
Gut and Liver 2022;16(4):535-546
Background/Aims:
We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.
Methods:
A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.
Results:
In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.
Conclusions
TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea
2.Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Tae Jung OH ; Jae Myung YU ; Kyung Wan MIN ; Hyun Shik SON ; Moon Kyu LEE ; Kun Ho YOON ; Young Duk SONG ; Joong Yeol PARK ; In Kyung JEONG ; Bong Soo CHA ; Yong Seong KIM ; Sei Hyun BAIK ; In Joo KIM ; Doo Man KIM ; Sung Rae KIM ; Kwan Woo LEE ; Jeong Hyung PARK ; In Kyu LEE ; Tae Sun PARK ; Sung Hee CHOI ; Sung Woo PARK
Diabetes & Metabolism Journal 2019;43(3):276-286
BACKGROUND: Combination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naïve newly-diagnosed type 2 diabetes mellitus. METHODS: A total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was measured at week 24. RESULTS: The reduction in the levels of HbA1c was −1.62%±0.07% in the vogmet group and −1.31%±0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of <6.5% (P=0.002) or <7% (P=0.039). Glycemic variability was also significantly improved with vogmet treatment, estimated by M-values (P=0.004). Gastrointestinal adverse events and hypoglycemia (%) were numerically lower in the vogmet-treated group. Moreover, a significant weight loss was observed with vogmet treatment compared with metformin (−1.63 kg vs. −0.86 kg, P=0.039). CONCLUSION: Vogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia.
Blood Glucose
;
Diabetes Mellitus, Type 2
;
Fasting
;
Glucose
;
Hemoglobin A, Glycosylated
;
Humans
;
Hypoglycemia
;
Metformin
;
Weight Loss
3.Serum Magnesium Level Is Associated with Type 2 Diabetes in Women with a History of Gestational Diabetes Mellitus: The Korea National Diabetes Program Study.
Sae Jeong YANG ; Soon Young HWANG ; Sei Hyun BAIK ; Kwan Woo LEE ; Moon Suk NAM ; Yong Soo PARK ; Jeong Taek WOO ; Young Seol KIM ; Sunmin PARK ; So Young PARK ; Chang Hoon YIM ; Hyun Koo YOON ; Sung Hoon KIM
Journal of Korean Medical Science 2014;29(1):84-89
Gestational diabetes mellitus (GDM) is a strong predictor of postpartum prediabetes and transition to overt type 2 diabetes (T2DM). Although many reports indicate that low magnesium is correlated with deteriorated glucose tolerance, the association between postpartum serum magnesium level and the risk for T2DM in women with a history of GDM has not been evaluated. We analyzed postpartum serum magnesium levels and development of prediabetes and T2DM in women with prior GDM according to American Diabetes Association (ADA) criteria using the Korean National Diabetes Program (KNDP) GDM cohort. During a mean follow-up of 15.6+/-2.0 months after screening, 116 women were divided into three groups according to glucose tolerance status. Ultimately, eight patients (6.9%) were diagnosed with T2DM, 59 patients (50.9%) with prediabetes, and 49 patients (42.2%) with normal glucose tolerance (NGT) after follow-up. The T2DM group had the lowest serum magnesium level (0.65 [0.63-0.68] mM/L) in the postpartum period, but there was no significant difference between the prediabetes group (0.70 [0.65-0.70] mM/L) and the NGT group (0.70 [0.65-0.70] mM/L) (P=0.073) Multiple logistic regression analysis showed that postpartum HOMA-IR was a significant predictor of both prediabetes and T2DM. Moreover, we found that postpartum serum magnesium level was also a possible predictor for T2DM development. Serum magnesium level in the postpartum period may be a possible predictor for T2DM development in women with a history of GDM.
Adult
;
Blood Glucose
;
Cohort Studies
;
Diabetes Mellitus, Type 2/*blood/diagnosis
;
Diabetes, Gestational/*blood
;
Female
;
Glucose Intolerance/*blood
;
Glucose Tolerance Test
;
Humans
;
Insulin Resistance
;
Magnesium/*blood
;
Postpartum Period/*blood
;
Prediabetic State/diagnosis
;
Pregnancy
;
Prospective Studies
;
Republic of Korea
;
Risk Factors
4.Three cases of glycogenic hepatopathy mimicking acute and relapsing hepatitis in type I diabetes mellitus.
Jae Hwang CHA ; Sang Ho RA ; Yu Mi PARK ; Yong Kwan JI ; Ji Hyun LEE ; So Yeon PARK ; Soon Koo BAIK ; Sang Ok KWON ; Mee Yon CHO ; Moon Young KIM
Clinical and Molecular Hepatology 2013;19(4):421-425
Glycogenic hepatopathy (GH) is an uncommon cause of serum transaminase elevation in type I diabetes mellitus (DM). The clinical signs and symptoms of GH are nonspecific, and include abdominal discomfort, mild hepatomegaly, and transaminase elevation. In this report we describe three cases of patients presenting serum transaminase elevation and hepatomegaly with a history of poorly controlled type I DM. All of the cases showed sudden elevation of transaminase to more than 30 times the upper normal range (like in acute hepatitis) followed by sustained fluctuation (like in relapsing hepatitis). However, the patients did not show any symptom or sign of acute hepatitis. We therefore performed a liver biopsy to confirm the cause of liver enzyme elevation, which revealed GH. Clinicians should be aware of GH so as to prevent diagnostic delay and misdiagnosis, and have sufficient insight into GH; this will be aided by the present report of three cases along with a literature review.
Acute Disease
;
Adult
;
Alanine Transaminase/blood
;
Aspartate Aminotransferases/blood
;
Delayed Diagnosis
;
Diabetes Mellitus, Type 1/complications/*pathology
;
Diagnostic Errors
;
Female
;
Glycogen Storage Disease/complications/*diagnosis/ultrasonography
;
Hepatitis/diagnosis
;
Hepatomegaly/complications/*diagnosis/ultrasonography
;
Humans
;
Liver/pathology
;
Recurrence
;
Young Adult
5.Insulin secretion and insulin resistance in Korean women with gestational diabetes mellitus and impaired glucose tolerance.
Sae Jeong YANG ; Tae Nyun KIM ; Sei Hyun BAIK ; Tae Sun KIM ; Kwan Woo LEE ; Moonsuk NAM ; Yong Soo PARK ; Jeong Teak WOO ; Young Seol KIM ; Sung Hoon KIM
The Korean Journal of Internal Medicine 2013;28(3):306-313
BACKGROUND/AIMS: The aim was to compare the insulin sensitivity and secretion index of pregnant Korean women with normal glucose tolerance (NGT), gestational impaired glucose tolerance (GIGT; only one abnormal value according to the Carpenter and Coustan criteria), and gestational diabetes mellitus (GDM). METHODS: A cross-sectional study was performed with 1,163 pregnant women with positive (1-hour plasma glucose > or = 7.2 mmol/L) in a 50-g oral glucose challenge test (OGCT). The 100-g oral glucose tolerance test (OGTT) was used to stratify the participants into three groups: NGT (n = 588), GIGT (n = 294), and GDM (n = 281). RESULTS: The GDM group had higher homeostasis model assessment of insulin resistance and lower insulin sensitivity index (ISOGTT), quantitative insulin sensitivity check index, homeostasis model assessment for estimation of index beta-cell secretion (HOMA-B), first and second phase insulin secretion, and insulin secretion-sensitivity index (ISSI) than the NGT group (p < or = 0.001 for all). Moreover, the GIGT group had lower ISOGTT, HOMA-B, first and second phase insulin secretion, and ISSI than the NGT group (p < 0.001 for all). Among the GIGT subjects, the 1-hour plasma glucose abnormal levels group showed significantly greater weight gain during pregnancy and higher values in the 50-g OGCT than the other two groups. Moreover, the 1-hour and 2-hour abnormal levels groups had poorer insulin secretion status than the 3-hour abnormal levels group. CONCLUSIONS: Korean women with GDM show impairments of both insulin secretion and insulin sensitivity. In addition, GIGT is associated with both beta-cell dysfunction and insulin resistance.
Adult
;
Cross-Sectional Studies
;
Diabetes, Gestational/*metabolism
;
Female
;
Glucose Tolerance Test
;
Humans
;
Insulin/*secretion
;
*Insulin Resistance
;
Pregnancy
6.Prevalence of Chronic Complications in Korean Patients with Type 2 Diabetes Mellitus Based on the Korean National Diabetes Program.
Sang Youl RHEE ; Suk CHON ; Mi Kwang KWON ; Ie Byung PARK ; Kyu Jeung AHN ; In Ju KIM ; Sung Hoon KIM ; Hyoung Woo LEE ; Kyung Soo KOH ; Doo Man KIM ; Sei Hyun BAIK ; Kwan Woo LEE ; Moon Suk NAM ; Yong Soo PARK ; Jeong taek WOO ; Young Seol KIM
Diabetes & Metabolism Journal 2011;35(5):504-512
BACKGROUND: The Korean National Diabetes Program (KNDP) cohort study is performing an ongoing large-scale prospective multicenter investigation to discover the pathogenesis of type 2 diabetes in Korean patients. This study was performed to examine the prevalence of chronic complications in patients with type 2 diabetes among those registered in the KNDP cohort within the past 4 years. METHODS: This study was performed between June 2006 and September 2009 at 13 university hospitals and included 4,265 KNDP cohort participants. Among the participants, the crude prevalence of microvascular and macrovascular diseases of those checked for diabetes-related complications was determined, and the adjusted standard prevalence and standardization of the general population prevalence ratio (SPR) was estimated based on the 2005 Korean National Health and Nutrition Examination Survey (KNHANES) population demographics. RESULTS: Among the KNDP registrants, 43.2% had hypertension, 34.8% had dyslipidemia, 10.8% had macrovascular disease, and 16.7% had microvascular disease. The SPR of the KNDP registrants was significantly higher than that of the KNHANES subjects after adjusting for demographics in the KNHANES 2005 population. However, with the exception of cardiovascular disease in females, the standardized prevalence for the most complicated items in the survey was significantly higher than that in the KNHANES subjects. CONCLUSION: The prevalence of macrovascular disease and peripheral vascular disease were significantly higher in Korean patients with type 2 diabetes than in the normal population. However, no significant difference was noted in the prevalence of cardiovascular disease in females.
Cardiovascular Diseases
;
Cerebrovascular Disorders
;
Cohort Studies
;
Coronary Disease
;
Demography
;
Diabetes Complications
;
Diabetes Mellitus, Type 2
;
Diabetic Retinopathy
;
Dyslipidemias
;
Female
;
Hospitals, University
;
Humans
;
Hypertension
;
Korea
;
Nutrition Surveys
;
Peripheral Vascular Diseases
;
Prevalence
;
Prospective Studies
7.Erratum: ACKNOWLEDGMENTS.
Sang Youl RHEE ; Suk CHON ; Mi Kwang KWON ; Ie Byung PARK ; Kyu Jeung AHN ; In Ju KIM ; Sung Hoon KIM ; Hyoung Woo LEE ; Kyung Soo KOH ; Doo Man KIM ; Sei Hyun BAIK ; Kwan Woo LEE ; Moon Suk NAM ; Yong Soo PARK ; Jeong taek WOO ; Young Seol KIM
Diabetes & Metabolism Journal 2011;35(6):643-643
No abstract available.
8.Endoscopic Sphincterotomy Plus Endoscopic Papillary Large Balloon Dilatation for Large Bile Duct Stones.
Seoung Joon HWANG ; Young Gyun KIM ; Kyu Chul LEE ; Myung Kwan JI ; Hyun Soo KIM ; Soon Goo BAIK ; Kuen Man LEE ; Jin Hyuck CHANG ; Min Su KIM ; Yong Han PAIK ; Se Joon LEE ; Hyo Jin PARK ; Kwan Sik LEE ; Sang In LEE ; Dong Ki LEE
Korean Journal of Gastrointestinal Endoscopy 2006;32(3):184-189
BACKGROUND/AIMS: The extraction of large common bile duct (CBD) stones after an endoscopic sphincterotomy (EST) is successful in 80~90% of cases but it often requires a prolonged time and repeated trials. This study investigated the utility of a combined endoscopic papillary large balloon dilatation (EPLBD) and a mid-incision of an EST (m-EST) method for the removal of large CBD stones. METHODS: Thirty patients with large CBD stones were enrolled in this study. EPLBD was carried out using the one-step inflation of a 15~18 mm diameter balloon after m-EST. RESULTS: The maximum stone diameter was 21.62+/-5.38 mm. Twelve patients had more than 4 stones, 7 patients had 2 stones, and the remainder had a single large stone. Complete ductal clearance was achieved in all patients. After the procedure, the serum amylase and/or lipase levels were elevated in 3 patients (13.3%). However, there was no episode of true pancreatitis. Minor bleeding was encountered in only one patient (3.3%), and was easily controlled by an endoscopic epinephrine injection. The procedure was carried out safely in 6 patients with periampullary diverticulum. No perforation or mortality was encountered. CONCLUSIONS: Combined EPLBD and m-EST is a safe and effective method, and may be a good alternative treatment for removing large CBD stones.
Amylases
;
Bile Ducts*
;
Bile*
;
Choledocholithiasis
;
Common Bile Duct
;
Dilatation*
;
Diverticulum
;
Epinephrine
;
Hemorrhage
;
Humans
;
Inflation, Economic
;
Lipase
;
Mortality
;
Pancreatitis
;
Sphincterotomy, Endoscopic*
9.Relationship between Childhood and Adolescent Obesity and Remnant Lipoprotein.
Yong Jun CHOI ; Young Eun JO ; Yun Kyung KIM ; Sang Mi AHN ; Seung Hee BAIK ; Sun Hye JUNG ; Hae Jin KIM ; Yoon Sok CHUNG ; Kwan Woo LEE ; Dae Jung KIM
Journal of Korean Society of Endocrinology 2006;21(4):311-318
BACKGROUND: Remnant lipoproteins are the lipolytic degradation product of the triglyceride-rich lipoproteins produced by the liver (very-low-density lipoprotein cholesterol) and intestine (chylomicrons). Recent studies have demonstrated a correlation between remnant lipoproteins and cardiovascular risk. Our study assessed the relationship between obesity and remnant lipoproteins and evaluated the factors related to remnant lipoprotein in children and adolescents. METHODS: Body mass index (BMI), waist circumference, systolic and diastolic blood pressures, body fat mass, total abdominal fat, visceral and subcutaneous fat areas, total cholesterol, triglyceride (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and remnant lipoprotein cholesterol (RLP-C) were measured in 135 children and adolescents (67 boys and 68 girls). Plasma RLP fractions were isolated using an immunoaffinity gel containing specific anti-apoB-100 and anti-apoA-I antibodies. The subjects were divided into three groups: the low (< 50 percentile), mid (50~84 percentile), and high (> or = 85 percentile) BMI groups. RESULTS: RLP-C was significantly correlated with age, sex, BMI, waist circumference, systolic and diastolic blood pressures, visceral and subcutaneous fat areas, visceral fat area to subcutaneous fat area ratio (VSR), total cholesterol, TG, HDL-C, apoB, and HOMA-IR. From a multivariate regression analysis, TG (beta = 0.928, P < 0.001) was found to be independently correlated with RLP-C. After excluding TG as an independent variable, a multivariate regression analysis revealed that the HOMA-IR (beta=0.231, P=0.007) and systolic blood pressure (beta=0.169, P=0.046) were independently associated with RLP-C. CONCLUSION: RLP-C was significantly higher in obese children and adolescents. TG, systolic blood pressure, and insulin resistance were related to remnant lipoproteins.
Abdominal Fat
;
Adipose Tissue
;
Adolescent*
;
Antibodies
;
Apolipoproteins B
;
Blood Pressure
;
Body Mass Index
;
Child
;
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Dyslipidemias
;
Humans
;
Insulin Resistance
;
Intestines
;
Intra-Abdominal Fat
;
Lipoproteins*
;
Liver
;
Obesity
;
Pediatric Obesity*
;
Plasma
;
Subcutaneous Fat
;
Triglycerides
;
Waist Circumference
10.Relationship between Childhood and Adolescent Obesity and Remnant Lipoprotein.
Yong Jun CHOI ; Young Eun JO ; Yun Kyung KIM ; Sang Mi AHN ; Seung Hee BAIK ; Sun Hye JUNG ; Hae Jin KIM ; Yoon Sok CHUNG ; Kwan Woo LEE ; Dae Jung KIM
Journal of Korean Society of Endocrinology 2006;21(4):311-318
BACKGROUND: Remnant lipoproteins are the lipolytic degradation product of the triglyceride-rich lipoproteins produced by the liver (very-low-density lipoprotein cholesterol) and intestine (chylomicrons). Recent studies have demonstrated a correlation between remnant lipoproteins and cardiovascular risk. Our study assessed the relationship between obesity and remnant lipoproteins and evaluated the factors related to remnant lipoprotein in children and adolescents. METHODS: Body mass index (BMI), waist circumference, systolic and diastolic blood pressures, body fat mass, total abdominal fat, visceral and subcutaneous fat areas, total cholesterol, triglyceride (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and remnant lipoprotein cholesterol (RLP-C) were measured in 135 children and adolescents (67 boys and 68 girls). Plasma RLP fractions were isolated using an immunoaffinity gel containing specific anti-apoB-100 and anti-apoA-I antibodies. The subjects were divided into three groups: the low (< 50 percentile), mid (50~84 percentile), and high (> or = 85 percentile) BMI groups. RESULTS: RLP-C was significantly correlated with age, sex, BMI, waist circumference, systolic and diastolic blood pressures, visceral and subcutaneous fat areas, visceral fat area to subcutaneous fat area ratio (VSR), total cholesterol, TG, HDL-C, apoB, and HOMA-IR. From a multivariate regression analysis, TG (beta = 0.928, P < 0.001) was found to be independently correlated with RLP-C. After excluding TG as an independent variable, a multivariate regression analysis revealed that the HOMA-IR (beta=0.231, P=0.007) and systolic blood pressure (beta=0.169, P=0.046) were independently associated with RLP-C. CONCLUSION: RLP-C was significantly higher in obese children and adolescents. TG, systolic blood pressure, and insulin resistance were related to remnant lipoproteins.
Abdominal Fat
;
Adipose Tissue
;
Adolescent*
;
Antibodies
;
Apolipoproteins B
;
Blood Pressure
;
Body Mass Index
;
Child
;
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Dyslipidemias
;
Humans
;
Insulin Resistance
;
Intestines
;
Intra-Abdominal Fat
;
Lipoproteins*
;
Liver
;
Obesity
;
Pediatric Obesity*
;
Plasma
;
Subcutaneous Fat
;
Triglycerides
;
Waist Circumference

Result Analysis
Print
Save
E-mail